Safety concerns spur FDA to again halt testing of Regenxbio gene therapy

Reports

3

Domains carrying it

3

First reported

24 August 2026

Latest report

31 August 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 24 August 2026Safety concerns spur FDA to again halt testing of Regenxbio gene therapybiopharmadive.com
2. 25 August 2026FDA Places New Clinical Hold On RGX-121 for Hunter Syndromecgtlive.com
3. 31 August 2026REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advancesstreetwisereports.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• uniQure seeks US approval for Huntington's gene therapy after FDA reversal3 reports · 3 domains · 2 September 2026
• Capricor soars on potential FDA review extension, filing amendments9 reports · 6 domains · 25 August 2026
• FDA Approves Gene Therapy for Glycogen Storage Disease Type 1a6 reports · 6 domains · 22 August 2026
• FDA Allows First Gene Therapy Clinical Trial for Ultra-Rare Pediatric Neurodegenerative Disease2 reports · 2 domains · 4 September 2026
• Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA ...2 reports · 2 domains · 24 August 2026
• Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With ...11 reports · 8 domains · 31 August 2026

◆ Share

◆ Evidence

3 reports · 3 domains

• REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advancesstreetwisereports.com · 31 August 2026
• FDA Places New Clinical Hold On RGX-121 for Hunter Syndromecgtlive.com · 25 August 2026
• Safety concerns spur FDA to again halt testing of Regenxbio gene therapybiopharmadive.com · 24 August 2026